上海神奇制药因信披违规收证监局行政监管措施决定书

Core Viewpoint - Shanghai Magical Pharmaceutical Investment Management Co., Ltd. has been sanctioned by the Shanghai Securities Regulatory Bureau for financial misconduct involving the misappropriation of sales expenses totaling 44,838,280 yuan in 2023, leading to errors in the annual report disclosure [1] Group 1: Regulatory Actions - The company received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau on September 26, 2025 [1] - The company is required to submit a rectification report within 30 days [1] - A warning letter has been issued to the former chairman, general manager, and financial director for their lack of diligence in their roles [1] Group 2: Financial Misconduct Details - The misconduct involved using a "basic drug promotion plan" to misappropriate sales expenses [1] - The company created fictitious accounts receivable through employee personal accounts, which were then reversed to credit impairment provisions [1] - This financial misconduct resulted in discrepancies in the company's 2023 annual report [1] Group 3: Company Response - The company has stated it will actively rectify the issues and standardize accounting practices [1] - The board members and relevant personnel will enhance their professional capabilities [1] - The regulatory measures imposed do not affect the company's normal operations [1]